Heart Attacks

Anthos Developing Hemostasis-Sparing Anticoagulant to Reduce Bleeding Hazard

Anticoagulants, Biotech, Blood Clots, Blood Thinner, Blood Vessels, Business, Cardiovascular Disease, Clinical Trials, Heart Attacks, Heart Disease, R&D, Start-Ups, Strokes, Thrombosis

Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.

September 10, 2020/by BioSpace

Severe Covid-19 riskier than heart attack for young adults; antibiotic shows no benefit

African-Americans, Antibiotics, Antimalarial, Azithromycin, Clinical Studies, Coronavirus Disease 2019 (COVID-19), Heart Attacks, Hispanics, Hospitalized COVID-19 Patients, Hydroxychloroquine, Lung Damage, Middle-Aged Adults, R&D, Surveys, Young Adults

A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.

September 9, 2020/by Andrew Humphreys

FDA approval for Brilinta, EU recommendation for Lynparza

Approvals, Blockbusters, BRCA mutation, Committee for Medicinal Products for Human Use (CHMP), Coronavirus Vaccines, European Medicines Agency, FDA, FDA/Regulatory, Heart Attacks, Metastatic pancreatic cancer, New Indications, Product Pipeline, Shares, Strokes

Britain’s AstraZeneca clinched expanded regulatory backing for two medications, including one for the blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine.

June 1, 2020/by BioSpace

Following Patient Death, Spring Bank Abandons Hepatitis B Program

Adverse Events, Business, Cardiac Events, Checkpoint Inhibitors, Clinical Trials, Heart Attacks, Hepatitis B, Patient Deaths, Product Pipeline, R&D, Solid Tumors, STING agonists, Strokes

Spring Bank Pharmaceuticals, based in Hopkinton, Massachusetts, is discontinuing development of inarigivir soproxil for chronic hepatitis B virus (HBV).

January 29, 2020/by BioSpace

FDA says Amarin can market fish-oil derived therapy for reducing heart attack risk

Heart Attacks, Strokes

U.S. health regulators approved expanding the heart benefit claims Amarin Corp. can make in promoting the company’s drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.

December 13, 2019/by Reuters Health

FDA panel unanimously backs expanding use of Amarin’s heart drug Vascepa

Cardiovascular Disease, Fish Oil, Heart Attacks, Strokes

A panel of experts to the U.S. FDA recommended allowing Amarin Corp. Plc’s fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.

November 14, 2019/by Reuters Health

Amarin surges as fish-oil drug receives largely positive FDA review

Cardiac Events, Cholesterol Lowering, FDA, FDA/Regulatory, Fish Oil, Heart Attacks, Mineral oil, Placebo, Potential Blockbusters, Shares, Statins, Strokes

Amarin Corp. Plc’s fish oil-derived drug and potential blockbuster Vascepa received a largely positive review from FDA staffers.

November 12, 2019/by Reuters Health

New Pharma Invention Index Picks AstraZeneca as Top Company

Artificial Intelligence, Business, Cancer, Cardiovascular (CV) Death, Chronic Kidney Disease, Coronary Heart Diseases, Heart Attacks, Idiopathic Pulmonary Fibrosis, Invention, Machine Learning, Oncology, Product Pipelines, Strokes, Type 2 Diabetes

AstraZeneca topped the first annual Pharmaceutical Invention Index, released by IDEA Pharma.

November 5, 2019/by BioSpace

FDA approves Farxiga for treating heart failure risk

Antidiabetics, Approvals, Blockbusters, Blood Sugar, Cardiovascular Risk, FDA, FDA/Regulatory, Heart Attacks, Heart Failure, Kidney Failure, New Indications, SGLT2 Inhibitors, Strokes, Type 2 Diabetes

AstraZeneca’s blockbuster drug Farxiga won U.S. approval as a treatment to reduce the chances of hospitalization for heart failure in adults with type 2 diabetes and other cardiovascular risks.

October 21, 2019/by Reuters Health

FDA Clears High Sensitivity Troponin-I Blood Test

Approvals, Blood Tests, British Medical Journal, Doctors, FDA, FDA/Regulatory, Heart Attack Diagnosis, Journal of the American Medical Association, The Lancet, Troponin blood tests

Abbott’s ARCHITECT STAT High Sensitivity Troponin-I blood test received clearance from the U.S. Food and Drug Administration to help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women.

September 25, 2019/by PR Newswire